160 related articles for article (PubMed ID: 10759618)
1. Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease.
Gerson LB; Hatton BN; Ryono R; Jones W; Pulliam G; Sampliner RE; Triadafilopoulos G; Fass R
Aliment Pharmacol Ther; 2000 Apr; 14(4):397-406. PubMed ID: 10759618
[TBL] [Abstract][Full Text] [Related]
2. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy.
Condra LJ; Morreale AP; Stolley SN; Marcus D
Am J Manag Care; 1999 May; 5(5):631-8. PubMed ID: 10537869
[TBL] [Abstract][Full Text] [Related]
3. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study.
Fass R; Murthy U; Hayden CW; Malagon IB; Pulliam G; Wendel C; Kovacs TO
Aliment Pharmacol Ther; 2000 Dec; 14(12):1595-603. PubMed ID: 11121907
[TBL] [Abstract][Full Text] [Related]
4. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
Frazzoni M; De Micheli E; Grisendi A; Savarino V
Aliment Pharmacol Ther; 2002 Jan; 16(1):35-9. PubMed ID: 11856076
[TBL] [Abstract][Full Text] [Related]
5. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
Newton M; Burnham WR; Kamm MA
Eur J Gastroenterol Hepatol; 1998 Sep; 10(9):753-8. PubMed ID: 9831269
[TBL] [Abstract][Full Text] [Related]
6. Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms.
Raisch DW; Klaurens LM; Hayden C; Malagon I; Pulliam G; Fass R
Dig Dis Sci; 2001 Jul; 46(7):1533-9. PubMed ID: 11478507
[TBL] [Abstract][Full Text] [Related]
7. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.
Franco MT; Salvia G; Terrin G; Spadaro R; De Rosa I; Iula VD; Cucchiara S
Dig Liver Dis; 2000 Nov; 32(8):660-6. PubMed ID: 11142573
[TBL] [Abstract][Full Text] [Related]
8. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Hall J; Dodd S; Durkin M; Sloan S
Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
[TBL] [Abstract][Full Text] [Related]
9. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
Mee AS; Rowley JL
Aliment Pharmacol Ther; 1996 Oct; 10(5):757-63. PubMed ID: 8899084
[TBL] [Abstract][Full Text] [Related]
10. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
Katz PO; Anderson C; Khoury R; Castell DO
Aliment Pharmacol Ther; 1998 Dec; 12(12):1231-4. PubMed ID: 9882031
[TBL] [Abstract][Full Text] [Related]
11. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole.
Nelson WW; Vermeulen LC; Geurkink EA; Ehlert DA; Reichelderfer M
Arch Intern Med; 2000 Sep; 160(16):2491-6. PubMed ID: 10979061
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R
Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
Nzeako UC; Murray JA
Aliment Pharmacol Ther; 2002 Jul; 16(7):1309-16. PubMed ID: 12144581
[TBL] [Abstract][Full Text] [Related]
14. Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
Frazzoni M; Grisendi A; Lanzani A; Melotti G; De Micheli E
Dig Liver Dis; 2002 Feb; 34(2):99-104. PubMed ID: 11926567
[TBL] [Abstract][Full Text] [Related]
15. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Jaspersen D; Diehl KL; Schoeppner H; Geyer P; Martens E
Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Remák E; Brown RE; Yuen C; Robinson A
Curr Med Res Opin; 2005 Oct; 21(10):1505-17. PubMed ID: 16238890
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
Freston JW
Am J Med; 2004 Sep; 117 Suppl 5A():14S-22S. PubMed ID: 15478848
[TBL] [Abstract][Full Text] [Related]
18. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitors or surgery for gastro-oesophageal reflux disease.
Hinder RA
Dig Liver Dis; 2002 Feb; 34(2):95-6. PubMed ID: 11926565
[No Abstract] [Full Text] [Related]
20. Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland.
Viljakka M; Nevalainen J; Isolauri J
Scand J Gastroenterol; 1997 Aug; 32(8):766-72. PubMed ID: 9282967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
